服药疗程对血脂康与辛伐他汀调脂效果的影响  

The influence of treating course on the lipld-regulating effect of Xuezhikang and Simvastati

作　　者：滕秋叶[1] 唐召力[1] 覃碧云[1] 张治坤[1] 唐海莲[1] 陈海玉[1] 

机构地区：[1]南方医科大学附属柳州医院重症医学科,545007

出　　处：《中国综合临床》2011年第9期910-913,共4页Clinical Medicine of China

基　　金：柳州市科技局科研课题（2008031405）

摘　　要：目的观察服药疗程对血脂康与辛伐他汀调脂效果的影响。方法将202例不稳定型心绞痛患者随机分为2组，其中辛伐他汀组98例，血脂康组104例。治疗前及治疗3、6个月后，分别检测血清胆固醇（TC）、甘油三酯（TG）、低密度脂蛋白胆固醇（LDL-C）、高密度脂蛋白胆固醇（HDL—C）含量。按照我国人群血脂分层的合适切点，将各组偏离TC、TG、LDL—C、HDL—C合适切点的病例筛选出来作进一步观察分析。结果辛伐他汀组和血脂康组服药3个月后即表现出明显的调脂效果，降低TC的有效率分别为40．6％（28／69）与60．9％（53／87）、降低LDL—C的有效率分别为51．2％（33／64）与84．5％（60／71）、升高HDL-C的有效率分别为22．2％（4／18）与61．5％（8／13），血脂康组的有效率明显高于辛伐他汀组，差异均有统计学意义（x2值分别为6．38、17．05和4．04，P〈0．05、P〈0．01、P〈0．05）。但服药6个月后，2组降TC的有效率分别为89．9％（62／69）与95．4％（83／87）、降LDL-C的有效率分别为89．1％（57／64）与97．2％（69／71）、升HDL-C的有效率分别为83．3％（15／18）与84．6％（11／13），差异均无统计学意义。辛伐他汀组与血脂康组3个月降TG有效率分别为9．5％（7／74）和24．5％（24／98）；6个月降TG有效率分别为51．4％（38／74）和68．4％（67／98）；2组比较差异均有统计学意义（X2值分别为6．45和5．13；P均〈0．05）。结论服药疗程影响血脂康和辛伐他汀调脂效果，血脂康起效更早，特别适合于合并高甘油三酯血症的冠心病患者。Objective To observe the influence of treating course on the lipid-regulating effect of Xuezhikang and Simvastati. Methods Two hundred and two patients with unstable angina pectoris（UAP） were randomly enrolled and divided into Simvastatin group （n = 98 ） and Xuezhikang group [ n = 104 ）. The TC, TG, LDL-C, HDL-C levels were measured before the treatment and at the 3rd, 6th month after the treatment. According to the suitable threshold of blood lipids in normal Chinese people, the patients who had abnormal blood lipids were picked out from the two groups for the further observation. Results The lipid- regulating effects of Simvastatin and Xuezhikang were showed up at the 3rd month, and the effective rate were 40. 6% and 60. 9% for TC regulation,51.2% and 84. 5% for LDL-C regulation,22. 2% and 61.5% for HDL-C regulation. We found significantly better effects of Xuezhikang than that of Simvastatin（ X2 = 6. 38,17.05,4. 04 ; P 〈 0. 05,P 〈 0. 01, P 〈 0. 05 ）. However, at the 6th month the effective rate of Simvastatin and Xuezhikang were 89. 9% and 95. d% for TC regulation,89. 1% and 97. 2% for LDL-C regulation,83.3% and 84.6% for HDL-C regulation, which showed no significant differences （X2 = 1.81,3.57, 0.01; Ps 〉 0.05）.The effective percentages of reduced TG level of Simvastatin and Xuezhikang were 9. 5% and 24. 5% at the 3rd month, 51.4% and 68.4% at the 6th month, which showed siznificant differences （ x2 = 6. 45.5.13 Ps 〈 0. 05） between the two groups at both time points. Conclusion The lipid-regulating effects of Xuezhikang and Simvastati were influenced by the treating period. Xuezhikang shows lipid-regulating effect more quickly, and it is recommended in treating CHD patients, especially for the patients with hypertriglyceridemia.

关 键 词：血脂康 辛伐他汀 不稳定型心绞痛 高脂血症 

分 类 号：R541.4[医药卫生—心血管疾病]